1
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-Part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
4
|
Gong J, Maia MC, Dizman N, Govindarajan A
and Pal SK: Metastasis in renal cell carcinoma: Biology and
implications for therapy. Asian J Urol. 3:286–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Song Z, Cao Q, Ruan H, Yang H, Wang K, Bao
L, Cheng G, Xu T, Xiao H, Wang C, et al: RCAN1.4 acts as a
suppressor of cancer progression and sunitinib resistance in clear
cell renal cell carcinoma. Exp Cell Res. 372:118–128. 2018.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Pichler M, Hutterer GC, Chromecki TF,
Jesche J, Kampel-Kettner K, Rehak P, Pummer K and Zigeuner R:
External validation of the leibovich prognosis score for
nonmetastatic clear cell renal cell carcinoma at a single European
center applying routine pathology. J Urology. 186:1773–1777. 2011.
View Article : Google Scholar
|
7
|
Novara G, Ficarra V, Antonelli A, Artibani
W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N,
Martignoni G, et al: Validation of the 2009 TNM version in a large
multi-institutional cohort of patients treated for renal cell
carcinoma: Are further improvements needed? Eur Urol. 58:588–595.
2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bergers G and Hanahan D: Modes of
resistance to anti-angio-genic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
9
|
Lai YJ, Tsai JC, Tseng YT, Wu MS, Liu WS,
Lam HI, Yu JH, Nozell SE and Benveniste EN: Small G protein Rac
GTPases regulate the maintenance of glioblastoma stem-like cells in
vitro and in vivo. Oncotarget. 8:1803–18049. 2017. View Article : Google Scholar
|
10
|
Bustelo XR, Sauzeau V and Berenjeno IM:
GTP-binding proteins of the Rho/Rac family: Regulation, effectors
and functions in vivo. Bioessays. 29:356–370. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Cancelas JA: On how Rac controls
hematopoietic stem cell activity. Transfusion. 51(Suppl 4):
153S–159S. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Aspenstrom P, Fransson A and Saras J: Rho
GTPases have diverse effects on the organization of the actin
filament system. Biochem J. 377:327–337. 2004. View Article : Google Scholar
|
13
|
Ridley AJ, Paterson HF, Johnston CL,
Diekmann D and Hall A: The small GTP-binding protein rac regulates
growth factor-induced membrane ruffling. Cell. 70:401–410. 1992.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Chen X, Zhang JX, Luo JH, Wu S, Yuan GJ,
Ma NF, Feng Y, Cai MY, Chen RX, Lu J, et al: CSTF2-induced
shortening of the RAC1 3'UTR promotes the pathogenesis of
urothelial carcinoma of the bladder. Cancer Res. 78:5848–5862.
2018.PubMed/NCBI
|
15
|
Pei H, Guo Z, Wang Z, Dai Y, Zheng L, Zhu
L, Zhang J, Hu W, Nie J, Mao W, et al: RAC2 promotes abnormal
proliferation of quiescent cells by enhanced JUNB expression via
the MAL-SRF pathway. Cell Cycle. 17:1115–1123. 2018. View Article : Google Scholar : PubMed/NCBI
|
16
|
Mack NA, Whalley HJ, Castillo-Lluva S and
Malliri A: The diverse roles of Rac signaling in tumorigenesis.
Cell Cycle. 10:1571–1581. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
RAC2 Rac family small GTPase 2 [Homo
sapiens (human)]. (Gene ID: 5880). NCBI; 2019, https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=5880
Accessed July 7 , 2019.
|
18
|
Filippi MD, Harris CE, Meller J, Gu Y,
Zheng Y and Williams DA: Localization of Rac2 via the C terminus
and aspartic acid 150 specifies superoxide generation, actin
polarity and chemotaxis in neutrophils. Nat Immunol. 5:744–751.
2004. View
Article : Google Scholar : PubMed/NCBI
|
19
|
Croker BA, Handman E, Hayball JD, Baldwin
TM, Voigt V, Cluse LA, Yang FC, Williams DA and Roberts AW:
Rac2-deficient mice display perturbed T-cell distribution and
chemotaxis, but only minor abnormalities in T(H)1 responses.
Immunol Cell Biol. 80:231–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yang FC, Kapur R, King AJ, Tao W, Kim C,
Borneo J, Breese R, Marshall M, Dinauer MC and Williams DA: Rac2
stimulates Akt activation affecting BAD/Bcl-XL expression while
mediating survival and actin function in primary mast cells.
Immunity. 12:557–568. 2000. View Article : Google Scholar : PubMed/NCBI
|
21
|
Fuhrman SA, Lasky LC and Limas C:
Prognostic significance of morphologic parameters in renal cell
carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
|
22
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th edition.
Springer Verlag; New York, NY: pp. 547–560. 2009
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
24
|
Cao Q, Ruan H, Wang K, Song Z, Bao L, Xu
T, Xiao H, Wang C, Cheng G, Tong J, et al: Overexpression of PLIN2
is a prognostic marker and attenuates tumor progression in clear
cell renal cell carcinoma. Int J Oncol. 53:137–147. 2018.PubMed/NCBI
|
25
|
Liu R, Qin X, Ji C, Zeng W, Yang Y and Tan
W: Pygopus 2 promotes kidney cancer OS-RC-2 cells proliferation and
invasion in vitro and in vivo. Asian J Urol. 2:151–157. 2015.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Yusenko MV, Zubakov D and Kovacs G: Gene
expression profiling of chromophobe renal cell carcinomas and renal
oncocytomas by Affymetrix GeneChip using pooled and individual
tumours. Int J Biol Sci. 5:517–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Jones J, Otu H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
28
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
29
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
30
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
31
|
Patard JJ, Leray E, Rodriguez A,
Rioux-Leclercq N, Guillé F and Lobel B: Correlation between symptom
graduation, tumor characteristics and survival in renal cell
carcinoma. Eur Urol. 44:226–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
32
|
Lee CT, Katz J, Fearn PA and Russo P: Mode
of presentation of renal cell carcinoma provides prognostic
information. Urol Oncol. 7:135–140. 2002. View Article : Google Scholar : PubMed/NCBI
|
33
|
Campbell SC, Novick AC, Belldegrun A,
Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ,
Matin SF, et al: Guideline for management of the clinical T1 renal
mass. J Urol. 182:1271–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
34
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus Everolimus in advanced
renal-cell carcinoma. New Engl J Med. 373:1803–1813. 2015.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Dempke WCM, Fenchel K, Uciechowski P and
Dale SP: Second- and third-generation drugs for immuno-oncology
treatment-the more the better? Eur J Cancer. 74:55–72. 2017.
View Article : Google Scholar : PubMed/NCBI
|
36
|
Li QK, Pavlovich CP, Zhang H, Kinsinger CR
and Chan DW: Challenges and opportunities in the proteomic
characterization of clear cell renal cell carcinoma (ccRCC): A
critical step towards the personalized care of renal cancers. Semin
Cancer Biol. 55:8–15. 2019. View Article : Google Scholar
|
37
|
Wang K, Ruan H, Song Z, Cao Q, Bao L, Liu
D, Xu T, Xiao H, Wang C, Cheng G, et al: PLIN3 is up-regulated and
correlates with poor prognosis in clear cell renal cell carcinoma.
Urol Oncol. 36:343.e9–343.e19. 2018. View Article : Google Scholar
|
38
|
Olson MF: Rho GTPases, their
post-translational modifications, disease-associated mutations and
pharmacological inhibitors. Small GTPases. 9:203–215. 2018.
View Article : Google Scholar :
|
39
|
Kazanietz MG and Caloca MJ: The Rac GTPase
in cancer: From old concepts to new paradigms. Cancer Res.
77:5445–5451. 2017. View Article : Google Scholar : PubMed/NCBI
|
40
|
Cardama GA, Gonzalez N, Maggio J, Menna PL
and Gomez DE: Rho GTPases as therapeutic targets in cancer
(Review). Int J Oncol. 51:1025–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
41
|
Casado-Medrano V, Baker MJ, Lopez-Haber C,
Cooke M, Wang S, Caloca MJ and Kazanietz MG: The role of Rac in
tumor susceptibility and disease progression: From biochemistry to
the clinic. Biochem Soc Trans. 46:1003–1012. 2018. View Article : Google Scholar : PubMed/NCBI
|
42
|
Kobayashi T, Inoue T, Shimizu Y, Terada N,
Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, et al:
Activation of Rac1 is closely related to androgen-independent cell
proliferation of prostate cancer cells both in vitro and in vivo.
Mol Endocrinol. 24:722–734. 2010. View Article : Google Scholar : PubMed/NCBI
|
43
|
Kamai T, Yamanishi T, Shirataki H, Takagi
K, Asami H, Ito Y and Yoshida K: Overexpression of RhoA, Rac1, and
Cdc42 GTPases is associated with progression in testicular cancer.
Clin Cancer Res. 10:4799–4805. 2004. View Article : Google Scholar : PubMed/NCBI
|
44
|
Leng R, Liao G, Wang H, Kuang J and Tang
L: Rac1 expression in epithelial ovarian cancer: Effect on cell EMT
and clinical outcome. Med Oncol. 32:3292015. View Article : Google Scholar : PubMed/NCBI
|
45
|
Zhou Y, Liao Q, Han Y, Chen J, Liu Z, Ling
H, Zhang J, Yang W, Oyang L, Xia L, et al: Rac1 overexpression is
correlated with epithelial mesenchymal transition and predicts poor
prognosis in non-small cell lung cancer. J Cancer. 7:2100–2109.
2016. View Article : Google Scholar : PubMed/NCBI
|
46
|
Ji J, Feng X, Shi M, Cai Q, Yu Y, Zhu Z
and Zhang J: Rac1 is correlated with aggressiveness and a potential
therapeutic target for gastric cancer. Int J Oncol. 46:1343–1353.
2015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Justilien V, Ali SA, Jamieson L, Yin N,
Cox AD, Der CJ, Murray NR and Fields AP: Ect2-Dependent rRNA
synthesis is required for KRAS-TRP53-driven lung adenocarcinoma.
Cancer Cell. 31:256–269. 2017. View Article : Google Scholar : PubMed/NCBI
|
48
|
Baker MJ, Cooke M and Kazanietz MG:
Nuclear PKC iota-ECT2-Rac1 and ribosome biogenesis: A novel axis in
lung tumorigenesis. Cancer Cell. 31:167–169. 2017. View Article : Google Scholar : PubMed/NCBI
|
49
|
Gao Y, Dickerson JB, Guo F, Zheng J and
Zheng Y: Rational design and characterization of a Rac
GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA.
101:7618–7623. 2004. View Article : Google Scholar : PubMed/NCBI
|
50
|
Troeger A and Williams DA:
Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood
disorders. Exp Cell Res. 319:2375–2383. 2013. View Article : Google Scholar : PubMed/NCBI
|
51
|
Mizukawa B, Wei J, Shrestha M, Wunderlich
M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA
and Mulloy JC: Inhibition of Rac GTPase signaling and downstream
prosurvival Bcl-2 proteins as combination targeted therapy in
MLL-AF9 leukemia. Blood. 118:5235–5245. 2011. View Article : Google Scholar : PubMed/NCBI
|
52
|
Gu Y and Williams DA: RAC2 GTPase
deficiency and myeloid cell dysfunction in human and mouse. J
Pediat Hematol Oncol. 24:791–794. 2002. View Article : Google Scholar
|